Arcus Biosciences (RCUS) News Today $9.08 -0.16 (-1.71%) Closing price 06/16/2025 03:59 PM EasternExtended Trading$8.90 -0.19 (-2.06%) As of 07:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RCUS Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Arcus Biosciences (NYSE:RCUS) Shares Down 3.8% - What's Next?Arcus Biosciences (NYSE:RCUS) Shares Down 3.8% - What's Next?June 11, 2025 | marketbeat.comStock Traders Purchase Large Volume of Call Options on Arcus Biosciences (NYSE:RCUS)Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) was the target of some unusual options trading on Wednesday. Investors bought 34,803 call options on the stock. This is an increase of 6,369% compared to the typical volume of 538 call options.June 11, 2025 | marketbeat.comCantor Fitzgerald Comments on RCUS FY2026 EarningsJune 11, 2025 | americanbankingnews.comArcus Biosciences Announces New Employment Inducement GrantsJune 10, 2025 | businesswire.comResearch Analysts Offer Predictions for RCUS FY2026 EarningsArcus Biosciences, Inc. (NYSE:RCUS - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for shares of Arcus Biosciences in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst L. Watsek forecasts that the company will post earnings peJune 10, 2025 | marketbeat.comH.C. Wainwright maintains Buy rating for Arcus Biosciences stockJune 4, 2025 | investing.comArcus Biosciences, Inc. (NYSE:RCUS) Short Interest Up 25.2% in MayArcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) was the recipient of a large growth in short interest during the month of May. As of May 15th, there was short interest totalling 9,900,000 shares, a growth of 25.2% from the April 30th total of 7,910,000 shares. Based on an average trading volume of 1,170,000 shares, the days-to-cover ratio is presently 8.5 days. Currently, 15.5% of the company's stock are sold short.June 4, 2025 | marketbeat.comArcus Biosciences (NYSE:RCUS) Trading 10.6% Higher - Here's What HappenedArcus Biosciences (NYSE:RCUS) Stock Price Up 10.6% - Should You Buy?June 4, 2025 | marketbeat.comNuveen Asset Management LLC Has $1.96 Million Position in Arcus Biosciences, Inc. (NYSE:RCUS)Nuveen Asset Management LLC reduced its holdings in shares of Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 22.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 131,859 shares of the company's stock after sellingJune 4, 2025 | marketbeat.comInitial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of ...June 1, 2025 | gurufocus.comInitial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed ResponseJune 1, 2025 | businesswire.comArcus Biosciences (NYSE:RCUS) Stock Price Down 8.6% - Time to Sell?Arcus Biosciences (NYSE:RCUS) Trading Down 8.6% - Should You Sell?May 31, 2025 | marketbeat.comArcus Biosciences, Inc. (NYSE:RCUS) Given Consensus Recommendation of "Moderate Buy" by BrokeragesArcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the eleven research firms that are currently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating, eight have assigned a buyMay 30, 2025 | marketbeat.comArcus Biosciences Announces New Employment Inducement GrantsMay 27, 2025 | businesswire.comArcus Biosciences, Inc. (NYSE:RCUS) Shares Bought by Millennium Management LLCMillennium Management LLC boosted its holdings in shares of Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 277.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 924,369 shares of thMay 25, 2025 | marketbeat.comWoodline Partners LP Purchases 45,497 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)Woodline Partners LP lifted its stake in Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 1.3% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,523,937 shares of the company's stock after buying an additional 45,497May 22, 2025 | marketbeat.comSuvretta Capital Management LLC Has $8.58 Million Stock Position in Arcus Biosciences, Inc. (NYSE:RCUS)Suvretta Capital Management LLC reduced its holdings in shares of Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 13.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 576,156 shares of the company's stock afMay 19, 2025 | marketbeat.comPoint72 Asset Management L.P. Sells 440,794 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)Point72 Asset Management L.P. reduced its holdings in shares of Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 18.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,996,279 shares of the company's stock afteMay 19, 2025 | marketbeat.comAmeriprise Financial Inc. Boosts Stake in Arcus Biosciences, Inc. (NYSE:RCUS)Ameriprise Financial Inc. raised its position in Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 17.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,547,591 shares of the company's stock after buyinMay 17, 2025 | marketbeat.comParkman Healthcare Partners LLC Acquires 248,035 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)Parkman Healthcare Partners LLC grew its holdings in shares of Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 24.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,273,789 shares of the company's stock after buying an additional 248,035 sharMay 16, 2025 | marketbeat.comOCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Stock Position in Arcus Biosciences, Inc. (NYSE:RCUS)OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 140.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 76,646 shares of theMay 16, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Invests $6.93 Million in Arcus Biosciences, Inc. (NYSE:RCUS)Jacobs Levy Equity Management Inc. purchased a new position in shares of Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 465,304 sharMay 16, 2025 | marketbeat.comCubist Systematic Strategies LLC Grows Position in Arcus Biosciences, Inc. (NYSE:RCUS)Cubist Systematic Strategies LLC raised its holdings in shares of Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 220.3% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 225,167 shares of the company's stock after purchasing an additional 154,874 sharMay 13, 2025 | marketbeat.comQ2 EPS Estimates for Arcus Biosciences Cut by HC WainwrightArcus Biosciences, Inc. (NYSE:RCUS - Free Report) - Investment analysts at HC Wainwright cut their Q2 2025 earnings per share (EPS) estimates for Arcus Biosciences in a research note issued on Wednesday, May 7th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings peMay 11, 2025 | marketbeat.comQ2 Earnings Forecast for Arcus Biosciences Issued By WedbushArcus Biosciences, Inc. (NYSE:RCUS - Free Report) - Research analysts at Wedbush cut their Q2 2025 earnings estimates for shares of Arcus Biosciences in a note issued to investors on Wednesday, May 7th. Wedbush analyst R. Driscoll now anticipates that the company will earn ($1.11) per share for tMay 11, 2025 | marketbeat.comRaymond James Financial Inc. Makes New Investment in Arcus Biosciences, Inc. (NYSE:RCUS)Raymond James Financial Inc. acquired a new position in shares of Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 35,662 sharesMay 11, 2025 | marketbeat.comArcus Biosciences, Inc. (NYSE:RCUS) Position Increased by Algert Global LLCAlgert Global LLC lifted its holdings in Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 59.6% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 180,122 shares of the company's stock after buying an additional 67,275 shares during the quMay 10, 2025 | marketbeat.comArcus Biosciences (NYSE:RCUS) Shares Gap Down Following Weak EarningsArcus Biosciences (NYSE:RCUS) Shares Gap Down After Earnings MissMay 9, 2025 | marketbeat.comWells Fargo & Company Lowers Arcus Biosciences (NYSE:RCUS) Price Target to $26.00Wells Fargo & Company reduced their price objective on Arcus Biosciences from $29.00 to $26.00 and set an "overweight" rating for the company in a research note on Wednesday.May 9, 2025 | marketbeat.comArcus Biosciences, Inc. (NYSE:RCUS) Shares Purchased by Dimensional Fund Advisors LPDimensional Fund Advisors LP grew its holdings in Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 11.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,702,302 shares of the company's stock after buying an additionMay 9, 2025 | marketbeat.comBraidwell LP Buys Shares of 802,100 Arcus Biosciences, Inc. (NYSE:RCUS)Braidwell LP purchased a new stake in Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 802,100 shares of the company's stock, valued at approximately $11May 8, 2025 | marketbeat.comSchonfeld Strategic Advisors LLC Sells 538,841 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)Schonfeld Strategic Advisors LLC reduced its position in Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 80.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 134,997 shares of the company's stock afteMay 8, 2025 | marketbeat.comRenaissance Technologies LLC Lowers Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS)Renaissance Technologies LLC cut its holdings in shares of Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 89.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 18,500 shares of the company's stock after selling 1May 8, 2025 | marketbeat.comArcus Biosciences, Inc. (NYSE:RCUS) Q1 2025 Earnings Call TranscriptMay 7, 2025 | msn.comQ1 2025 Arcus Biosciences Inc Earnings CallMay 7, 2025 | finance.yahoo.comArcus Biosciences, Inc. (RCUS) Q1 2025 Earnings Call TranscriptMay 6, 2025 | seekingalpha.comArcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline UpdateMay 6, 2025 | gurufocus.comArcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline UpdateMay 6, 2025 | businesswire.comArcus Biosciences, Inc. (NYSE:RCUS) Receives Average Recommendation of "Buy" from BrokeragesArcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) has earned an average recommendation of "Buy" from the ten analysts that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a hold recommendation, eight have assigned a buy recommendation andMay 6, 2025 | marketbeat.comArcus Biosciences Q1 2025 Earnings PreviewMay 5, 2025 | msn.comBoxer Capital Management LLC Makes New $23.86 Million Investment in Arcus Biosciences, Inc. (NYSE:RCUS)Boxer Capital Management LLC acquired a new stake in Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 1,602,200 shares of the company's stock, valued at approximately $23May 4, 2025 | marketbeat.comPDT Partners LLC Acquires 38,116 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)PDT Partners LLC lifted its holdings in Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 43.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 125,752 shares of the company's stock after acquiring an addMay 2, 2025 | marketbeat.comArcus Biosciences (RCUS) Expected to Announce Quarterly Earnings on TuesdayArcus Biosciences (NYSE:RCUS) will be releasing its Q1 2025 earnings before the market opens on Tuesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-6-arcus-biosciences-inc-stock/)May 1, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Buys New Stake in Arcus Biosciences, Inc. (NYSE:RCUS)Adage Capital Partners GP L.L.C. bought a new stake in Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 443,000 shares of the company's stock, valued at approximately $6,596,000. Adage Capital PartnersMay 1, 2025 | marketbeat.comArcus Biosciences, Inc. (NYSE:RCUS) Shares Bought by Invesco Ltd.Invesco Ltd. grew its stake in Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 21.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 203,987 shares of the company's stock after buying an additApril 29, 2025 | marketbeat.comArcus Biosciences, Inc. (NYSE:RCUS) Shares Sold by Decheng Capital LLCDecheng Capital LLC reduced its stake in Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 7.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 808,789 shares of the company's stock after selling 61,April 28, 2025 | marketbeat.comArcus Biosciences Announces New Employment Inducement GrantsApril 24, 2025 | businesswire.comDiadema Partners LP Acquires New Shares in Arcus Biosciences, Inc. (NYSE:RCUS)Diadema Partners LP bought a new position in Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 165,965 shares of the company's stoApril 24, 2025 | marketbeat.comArcus Biosciences to Present First Combination Data for HIF-2a Inhibitor Casdatifan Plus Cabozantinib in an Oral Presentation at the 2025 ASCO Annual MeetingApril 23, 2025 | businesswire.comArcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline UpdateApril 22, 2025 | businesswire.com Get Arcus Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RCUS and its competitors with MarketBeat's FREE daily newsletter. Email Address RCUS Media Mentions By Week RCUS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RCUS News Sentiment▼0.750.90▲Average Medical News Sentiment RCUS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RCUS Articles This Week▼96▲RCUS Articles Average Week Get Arcus Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RCUS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PTC Therapeutics News Today Cytokinetics News Today Avidity Biosciences News Today Krystal Biotech News Today Sarepta Therapeutics News Today Merus News Today ACADIA Pharmaceuticals News Today Arcellx News Today SpringWorks Therapeutics News Today Ultragenyx Pharmaceutical News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:RCUS) was last updated on 6/17/2025 by MarketBeat.com Staff From Our PartnersThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcus Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcus Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RCUS Stock Free RCUS Stock Alerts